About MonTa Biosciences
MonTa Biosciences is a company based in Copenhagen (Denmark) founded in 2013 by Thomas Lars Andresen. MonTa Biosciences has raised $3.97 million across 3 funding rounds from investors including PreSeed Ventures and Novo Holdings. The company has 4 employees as of November 30, 2024. MonTa Biosciences offers products and services including MBS8. MonTa Biosciences operates in a competitive market with competitors including Jazz Pharmaceuticals, BeiGene, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter Copenhagen, Denmark
- Employees 4 as on 30 Nov, 2024
- Founders Thomas Lars Andresen
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Monta Biosciences Aps
-
Annual Revenue
Not available
-
Net Profit
-$203.83 K (USD)-202as on Dec 31, 2022
-
EBITDA
-$458.7 K (USD)-24as on Dec 31, 2022
-
Total Equity Funding
$3.97 M (USD)
in 3 rounds
-
Latest Funding Round
$3.49 M (USD), Series A
Jan 22, 2019
-
Investors
PreSeed Ventures
& 1 more
-
Employee Count
4
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MonTa Biosciences
MonTa Biosciences offers a comprehensive portfolio of products and services, including MBS8.
LNP-based drug to enhance immune response against tumors
People of MonTa Biosciences
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of MonTa Biosciences
MonTa Biosciences has successfully raised a total of $3.97M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3.49 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MonTa Biosciences
MonTa Biosciences has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include PreSeed Ventures and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for MonTa Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MonTa Biosciences
Investment portfolio details for MonTa Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MonTa Biosciences
Detailed financials for MonTa Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Monta Biosciences Comparisons
Peer comparison for MonTa Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MonTa Biosciences
MonTa Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BeiGene, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of MonTa Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Monta Biosciences
Complete news archive for MonTa Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MonTa Biosciences
MonTa Biosciences was founded in 2013 and raised its 1st funding round 1 year after it was founded.
MonTa Biosciences is headquartered in Copenhagen, Denmark.
MonTa Biosciences is a funded company, having raised a total of $3.97M across 3 funding rounds to date.
As of Nov 30, 2024, the latest employee count at MonTa Biosciences is 4.
MonTa Biosciences was founded in 2013 in Copenhagen, Denmark, and operates in the biotechnology sector. Liposome-based drug delivery technology is utilized to transport immune-stimulating compounds directly to immune cells in the blood for cancer treatment. The lead candidate consists of a liposome formulation of a TLR7 agonist, which stimulates the innate immune system. Development is planned in combination with radiation, chemotherapy, therapeutic antibodies, biologics, kinase inhibitors, and surgery.
MonTa Biosciences's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and BeiGene.
MonTa Biosciences offers MBS8.
MonTa Biosciences has 2 investors. Key investors include PreSeed Ventures, and Novo Holdings.
The valuation of MonTa Biosciences is $12.24M as of Jan 2019.